Jianhui Zhuang1, Pompilio Faggiano, Qi Li, Danitza Pradelli, Vet Med, Wenhui Peng, Mei Zuo, Yawei Xu. 1. aDepartment of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China bCardiology Division, Spedali Civili and University of Brescia, Brescia, Italy cDepartment of Geriatrics, the 113th Hospital of Chinese People's Liberation Army, Ningbo, China dSection of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy eDepartment of Blood Transfusion, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China *Jianhui Zhuang and Pompilio Faggiano contributed equally to the writing of the study.
Abstract
AIMS: An increasing number of clinical studies have explored the possibility of using tumor biomarker carbohydrate antigen 125 (CA 125) in the management of patients with heart failure. This systematic review and meta-analysis was performed to comprehensively summarize the available evidence and evaluate the applicability of CA 125 in heart failure. METHODS: We searched PubMed, Embase, and Cochrane Central Register of controlled trials. Of the 253 studies identified, 23 studies investigating the application of CA 125 in the clinical management of heart failure were included for meta-analyses and systematic review. RESULTS: The serum levels of CA 125 increased significantly in heart failure patients compared with healthy controls (standardized mean difference of 1.49 U/ml, P < 0.001). The fluctuation of CA 125 was closely associated with echocardiographic parameters. Likewise, the CA 125 levels were positively correlated with brain natriuretic peptide and N-terminal pro-BNP. Further investigation found that CA 125 levels increased accordingly as cardiac function declined from the New York Heart Association class I/II to class III and further from class III to IV [1.58, 95% confidence interval (0.75-2.41) and 1.37, 95% confidence interval (0.76-1.98) U/ml, respectively]. Heart failure patients with poor outcomes showed higher CA 125 level relative to those without adverse effects in short-term or long-term follow-up. CONCLUSION: CA 125 is a promising biomarker in the diagnosis, stratification, and outcome evaluation of heart failure patients. CA 125 may be regarded as a surrogate marker of echocardiographic variables, N-terminal pro-BNP and brain natriuretic peptide.
AIMS: An increasing number of clinical studies have explored the possibility of using tumor biomarker carbohydrate antigen 125 (CA 125) in the management of patients with heart failure. This systematic review and meta-analysis was performed to comprehensively summarize the available evidence and evaluate the applicability of CA 125 in heart failure. METHODS: We searched PubMed, Embase, and Cochrane Central Register of controlled trials. Of the 253 studies identified, 23 studies investigating the application of CA 125 in the clinical management of heart failure were included for meta-analyses and systematic review. RESULTS: The serum levels of CA 125 increased significantly in heart failurepatients compared with healthy controls (standardized mean difference of 1.49 U/ml, P < 0.001). The fluctuation of CA 125 was closely associated with echocardiographic parameters. Likewise, the CA 125 levels were positively correlated with brain natriuretic peptide and N-terminal pro-BNP. Further investigation found that CA 125 levels increased accordingly as cardiac function declined from the New York Heart Association class I/II to class III and further from class III to IV [1.58, 95% confidence interval (0.75-2.41) and 1.37, 95% confidence interval (0.76-1.98) U/ml, respectively]. Heart failurepatients with poor outcomes showed higher CA 125 level relative to those without adverse effects in short-term or long-term follow-up. CONCLUSION:CA 125 is a promising biomarker in the diagnosis, stratification, and outcome evaluation of heart failurepatients. CA 125 may be regarded as a surrogate marker of echocardiographic variables, N-terminal pro-BNP and brain natriuretic peptide.
Authors: Ka Hou Christien Li; Mengqi Gong; Guangping Li; Adrian Baranchuk; Tong Liu; Martin C S Wong; Aaron Jesuthasan; Rachel W C Lai; Jenny Chi Ling Lai; Alex Pui Wai Lee; Antoni Bayés-Genis; Rafael de la Espriella; Juan Sanchis; William K K Wu; Gary Tse; Julio Nuñez Journal: Heart Asia Date: 2018-10-26
Authors: Patrícia Lourenço; Filipe M Cunha; Catarina Elias; Catarina Fernandes; Isaac Barroso; João T Guimarães; Paulo Bettencourt Journal: ESC Heart Fail Date: 2022-01-05
Authors: Angel Cheung; Mengqi Gong; Roberto Bellanti; Sadeq Ali-Hasan-Al-Saegh; Guangping Li; Eulàlia Roig; Julio Núñez; Thomas D Stamos; Mehmet Birhan Yilmaz; Kaya Hakki; William K K Wu; Sunny Hei Wong; Wing Tak Wong; George Bazoukis; Konstantinos Lampropoulos; Lah Ah Tse; Jichao Zhao; Gregory Y H Lip; Adrian Baranchuk; Martin C S Wong; Tong Liu; Gary Tse Journal: Heart Asia Date: 2018-01-07